Characterization of human adipose tissue-derived stromal cells isolated from diabetic patient's distal limbs with critical ischemia

Cell Biochemistry and Function

Volumn 32, Issue 7, 2014, Pages 597-604

  Kočí, Zuzana ^a,b   Turnovcová, Karolína ^a   Dubský, Michal ^c   Baranovičová, Lenka ^a   Holáň, Vladimír ^a   Chudíčková, Milada ^a   Syková, Eva ^a,b   Kubinová, Šárka ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Adipose tissue; Cell therapy; Diabetes; Differentiation; Flow cytometry; Mesenchymal stem cells

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; CYTOKINE; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; VASCULOTROPIN A;

ADIPOCYTE; ADULT; AGED; CARTILAGE CELL; CASE CONTROL STUDY; CELL DIFFERENTIATION; CYTOLOGY; DIABETES MELLITUS; DIABETIC FOOT; FEMALE; FIBROBLAST; HUMAN; ISCHEMIA; LIMB; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; OSTEOBLAST; PATHOLOGY; STROMA CELL; SUBCUTANEOUS FAT; VASCULARIZATION; VERY ELDERLY;

ADIPOCYTES; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CHONDROCYTES; CYTOKINES; DIABETES MELLITUS; DIABETIC FOOT; EXTREMITIES; FEMALE; FIBROBLASTS; HUMANS; ISCHEMIA; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OSTEOBLASTS; RECEPTORS, CELL SURFACE; STROMAL CELLS; SUBCUTANEOUS FAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84913603153     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3056     Document Type: Article

References (40)

1. Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells (Dayton, Ohio) 2011; 29: 5-10.
2. Dubsky M, Jirkovska A, Bem R, et al. Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. Diabetes Metab Res Rev 2013; 29: 369-376.
3. Klepanec A, Mistrik M, Altaner C, et al. No difference in intra-arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplant 2012; 21: 1909-1918.
4. Altaner C, Altanerova V, Cihova M, et al. Characterization of mesenchymal stem cells of " no-options" patients with critical limb ischemia treated by autologous bone marrow mononuclear cells. PLoS One 2013; 8: e73722.
5. Mizuno H, Tobita M, Uysal AC. Concise review: adipose-derived stem cells as a novel tool for future regenerative medicine. Stem Cells (Dayton, Ohio) 2012; 30: 804-810.
6. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol 2006; 24: 150-154.
7. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells (Dayton, Ohio) 2006; 24: 1294-1301.
8. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007; 100: 1249-1260.
9. Smadja DM, d'Audigier C, Guerin CL, et al. Angiogenic potential of BM MSCs derived from patients with critical leg ischemia. Bone Marrow Transplant 2012; 47: 997-1000.
10. Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004; 109: 1292-1298.
11. Lee J, Han DJ, Kim SC. In vitro differentiation of human adipose tissue-derived stem cells into cells with pancreatic phenotype by regenerating pancreas extract. Biochem Biophys Res Commun 2008; 375: 547-551.
12. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-2786.
13. Fadini GP, Sartore S, Agostini C, Avogaro A. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care 2007; 30: 1305-1313.
14. Phadnis SM, Ghaskadbi SM, Hardikar AA, Bhonde RR. Mesenchymal stem cells derived from bone marrow of diabetic patients portrait unique markers influenced by the diabetic microenvironment. Rev Diabet Stud 2009; 6: 260-270.
15. Cramer C, Freisinger E, Jones RK, et al. Persistent high glucose concentrations alter the regenerative potential of mesenchymal stem cells. Stem Cells Dev 2010; 19: 1875-1884.
16. Acosta L, Hmadcha A, Escacena N, et al. Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity. Diabetes 2013; 62: 4266-4269.
17. Bura A, Planat-Benard V, Bourin P, et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy 2014; 16: 245-257.
18. Ferrer-Lorente R, Bejar MT, Tous M, Vilahur G, Badimon L. Systems biology approach to identify alterations in the stem cell reservoir of subcutaneous adipose tissue in a rat model of diabetes: effects on differentiation potential and function. Diabetologia 2014; 57: 246-256.
19. Kim HK, Kim YJ, Kim JT, et al. Alterations in the proangiogenic functions of adipose tissue-derived stromal cells isolated from diabetic rats. Stem Cells Dev 2008; 17: 669-680.
20. Cianfarani F, Toietta G, Di Rocco G, et al. Diabetes impairs adipose tissue-derived stem cell function and efficiency in promoting wound healing. Wound Repair Regen 2013; 21: 545-553.
21. Shin L, Peterson DA. Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem Cells Transl Med 2012; 1: 125-135.
22. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
23. Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy 2013; 15: 641-648.
24. Patel P, Abate N. Role of subcutaneous adipose tissue in the pathogenesis of insulin resistance. J Obes 2013; 2013: 489187.
25. Toyoda M, Matsubara Y, Lin K, Sugimachi K, Furue M. Characterization and comparison of adipose tissue-derived cells from human subcutaneous and omental adipose tissues. Cell Biochem Funct 2009; 27: 440-447.
26. Alt E, Yan Y, Gehmert S, et al. Fibroblasts share mesenchymal phenotypes with stem cells, but lack their differentiation and colony-forming potential. Biol Cell 2011; 103: 197-208.
27. Blasi A, Martino C, Balducci L, et al. Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential. Vasc Cell 2011; 3: 5.
28. Haniffa MA, Wang XN, Holtick U, et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007; 179: 1595-1604.
29. Halfon S, Abramov N, Grinblat B, Ginis I. Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev 2011; 20: 53-66.
30. Turnovcova K, Ruzickova K, Vanecek V, Sykova E, Jendelova P. Properties and growth of human bone marrow mesenchymal stromal cells cultivated in different media. Cytotherapy 2009; 11: 874-885.
31. Mitchell JB, McIntosh K, Zvonic S, et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells 2006; 24: 376-385.
32. Traktuev DO, Merfeld-Clauss S, Li J, et al. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res 2008; 102: 77-85.
33. Maumus M, Peyrafitte JA, D'Angelo R, et al. Native human adipose stromal cells: localization, morphology and phenotype. Int J Obes 2011; 35: 1141-1153.
34. Zimmerlin L, Donnenberg VS, Rubin JP, Donnenberg AD. Mesenchymal markers on human adipose stem/progenitor cells. Cytometry A 2013; 83: 134-140.
35. Baer PC, Geiger H. Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity. Stem Cells Int 2012; 2012: 812693.
36. Roemeling-van Rhijn M, Mensah FK, Korevaar SS, et al. Effects of hypoxia on the immunomodulatory properties of adipose tissue-derived mesenchymal stem cells. Front Immunol 2013; 4: 203.
37. Pasarica M, Sereda OR, Redman LM, et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009; 58: 718-725.
38. Valorani MG, Montelatici E, Germani A, et al. Pre-culturing human adipose tissue mesenchymal stem cells under hypoxia increases their adipogenic and osteogenic differentiation potentials. Cell Prolif 2012; 45: 225-238.
39. Tamama K, Kawasaki H, Kerpedjieva SS, et al. Differential roles of hypoxia inducible factor subunits in multipotential stromal cells under hypoxic condition. J Cell Biochem 2011; 112: 804-817.
40. Hung SC, Pochampally RR, Hsu SC, et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2007; 2: e416.